Crescent Biopharma CBIO
NASDAQ CBIO
$16.23 -1.09 (-6.29%)
At close: Aug 20, 2026 · 4:00 PM EDT

Crescent Biopharma (CBIO) EBT Margin (2013 - 2026)

Crescent Biopharma (CBIO) posted quarterly EBT Margin of 7341.87% for Q1 2026, up 58.5% quarter-over-quarter from 17690.09% in Q2 2022.

Crescent Biopharma (CBIO) EBT Margin (2013 - 2026) Analysis & Trends

Crescent Biopharma (CBIO) has reported EBT Margin for 8 consecutive years, with 7341.87% the latest figure, recorded in Q1 2026.

  • In Q1 2026, EBT Margin changed N/A year-over-year to 7341.87%; the TTM figure through Jun 2026 stood at 22226.95% (changed N/A YoY), while the FY2025 annual figure was 1401.16%, changed N/A from the prior year.
  • EBT Margin grew to 7341.87% in Q1 2026 per CBIO's latest filing, from 17690.09% in the prior quarter.
  • Across five years, EBT Margin topped out at 7341.87% in Q1 2026 and bottomed at 17690.09% in Q2 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Margin (Qtr)
1 Vertex Pharmaceuticals 137.11 Bn 129.26 Bn 2.84 Bn 41.75%
2 Regeneron Pharmaceuticals 84.98 Bn 76.99 Bn 3.93 Bn 35.61%
3 Argenx Se 64.52 Bn 59.33 Bn 1.37 Bn 35.71%
4 Moderna 53.23 Bn 48.09 Bn 52.00 Mn -528.97%
5 BeOne Medicines 41.23 Bn 36.14 Bn 1.53 Bn 18.33%
6 Alnylam Pharmaceuticals 30.65 Bn 27.34 Bn 992.69 Mn 13.77%
7 Insmed 27.15 Bn 25.99 Bn 358.27 Mn -2.67%
8 Royalty Pharma 26.98 Bn 26.14 Bn - 12.09%
9 BioNTech SE 26.78 Bn 8.39 Bn 668.28 Mn -25.06%
10 Crescent Biopharma 1.05 Bn 875.92 Mn - -

Historic Data

Download Data
DateValue
Mar 31, 2026 -7,341.87%
Jun 30, 2022 -17,690.09%
Dec 31, 2021 -98,847.07%
Sep 30, 2021 -20,023.48%
Jun 30, 2021 -10,140,324.65%
Mar 31, 2021 -1,352.43%
Dec 31, 2020 -9,551.50%
Sep 30, 2020 -1,372.25%
Mar 31, 2020 -85.14%
Sep 30, 2016 -48,631.11%
Dec 31, 2015 -136,605.83%
Sep 30, 2015 -20,263.10%
Jun 30, 2015 51.95%
Jun 30, 2014 53.69%
Dec 31, 2013 -39,167.15%
Sep 30, 2013 -7,039.78%
Jun 30, 2013 -6,349.75%
Mar 31, 2013 12.05%